Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population.

Abstract

Prior authorization for PPIs had the effect of reducing use of high-cost PPIs, while encouraging use of lower costing H2As without evidence of adverse medical consequences.